Notice of Intent to Publish the Reissuance of PAR-16-042 Drug Discovery For Nervous System Disorders (R21 Clinical Trial Not Allowed) – Scholarship and Grants Opportunities

0
28
Opportunity ID: 309444
Opportunity Number: NOT-MH-18-055
Opportunity Title: Notice of Intent to Publish the Reissuance of PAR-16-042 Drug Discovery For Nervous System Disorders (R21 Clinical Trial Not Allowed)
Opportunity Category: Discretionary
Opportunity Category Explanation:
Funding Instrument Type: Grant
Category of Funding Activity: Health
Category Explanation:
CFDA Number(s): 93.242
Eligible Applicants: State governments
County governments
City or township governments
Special district governments
Independent school districts
Public and State controlled institutions of higher education
Native American tribal governments (Federally recognized)
Public housing authorities/Indian housing authorities
Native American tribal organizations (other than Federally recognized tribal governments)
Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
Private institutions of higher education
For profit organizations other than small businesses
Small businesses
Others (see text field entitled “Additional Information on Eligibility” for clarification)
Additional Information on Eligibility:
Agency Code: HHS-NIH11
Agency Name: Department of Health and Human Services
National Institutes of Health
Posted Date: Oct 04, 2018
Estimated Synopsis Post Date: Jan 09, 2019
Fiscal Year: 2019
Award Ceiling:
Award Floor:
Estimated Total Program Funding:
Expected Number of Awards:
Description: The National Institute of Mental Health, along with the National Institute on Drug Abuse (NIDA) and National Institute on Aging (NIA), informs the community that the following FOA and its companions will be reissued: PAR-16-042 Drug Discovery For Nervous System Disorders (R21). This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and appropriate projects. The FOA will be published in Winter 2019 for The February Receipt Dates. The FOA will continue to utilize the R21 Grant mechanism.
Version: 1

Visit the Official Webpage For More Details on Notice of Intent to Publish the Reissuance of PAR-16-042 Drug Discovery For Nervous System Disorders (R21 Clinical Trial Not Allowed)

LEAVE A REPLY

Please enter your comment!
Please enter your name here